Lindsay A. Renfro, PhD

Associate Professor of Research Population and Public Health Sciences

Children's Oncology Group Associate Group Statistician

Image of Lindsay A. Renfro, PhD
Is this your profile? Click to edit

Overview

Dr. Lindsay Renfro is an Associate Professor of Research at the University of Southern California and the Associate Group Statistician for Children’s Oncology Group (COG). COG is the pediatric cooperative group member of the NIH/NCI’s National Clinical Trials Network and the world’s largest organization dedicated exclusively to pediatric cancer research. Within COG, Dr. Renfro is also a faculty statistician for the Renal Tumors Committee, where she leads the design and analysis of therapeutic and biology-driven clinical trials for Wilms Tumor and related projects in pediatric renal cancer. Her expertise and methodological interests also include novel trial designs (e.g., adaptive, Bayesian, biomarker-driven, and master protocols), evaluation and validation of surrogate endpoints in clinical trials, and construction, validation, and implementation of disease-specific prognostic calculators for clinical use and decision-making. Dr. Renfro also enjoys teaching statistics to non-statisticians, mentoring students, traveling, and enjoying the mountains and beaches of Southern California with her son, Will.

Awards

  • Texas Woman’s University: Hallmark Alumni Award, 2018
  • Mayo Clinic: KL2 Mentored Career Development Award, 2015-2018
  • ENAR / International Biometric Society: Distinguished Student Paper Award, 2011
  • National Science Foundation, National Center for Education Statistics: Fellow, National Summer Data Policy Institute, 2010
  • Association for Institutional Research, National Center for Education Statistics: AIR/NCES Graduate Fellowship, 2008-2010
  • Association for Institutional Research: Best Paper Award, 2007
  • Baylor University: Dean’s Stipend Enhancement Award, 2006-2011
  • Kappa Mu Epsilon National Mathematics Honor Society: Best Paper Award, 2005
  • Texas Woman’s University: Chancellor’s Research Scholar, 2005
  • Texas Woman’s University: Harlan Miller Award and Memorial Scholarship, 2004-2005
  • Texas Instruments: Women in Engineering Award and Scholarship, 2003-2005
  • Texas Woman’s University: Hallmark Alumni Award, 2018
  • Mayo Clinic: KL2 Mentored Career Development Award, 2015 – 2018
  • ENAR / International Biometric Society: Distinguished Student Paper Award, 2011
  • Baylor University: Dean’s Stipend Enhancement Award, 2006 – 2011
  • National Science Foundation, National Center for Education Statistics: Fellow, National Summer Data Policy Institute, 2010
  • Association for Institutional Research, National Center for Education Statistics: AIR/NCES Graduate Fellowship, 2008 – 2010
  • Association for Institutional Research: Best Paper Award, 2007
  • Kappa Mu Epsilon National Mathematics Honor Society: Best Paper Award, 2005
  • Texas Woman’s University: Chancellor’s Research Scholar, 2005
  • Texas Woman’s University: Harlan Miller Award and Memorial Scholarship, 2004 – 2005
  • Texas Instruments: Women in Engineering Award and Scholarship, 2003 – 2005

Publications

  • Treatment and outcomes of clear cell sarcoma of the kidney: A report from the Children’s Oncology Group studies AREN0321 and AREN03B2 Cancer. 2024 Feb 23. . View in PubMed
  • Race and Ethnic Group Enrollment and Outcomes for Wilms Tumor: Analysis of the Current Era Children’s Oncology Group Study AREN03B2 J Am Coll Surg. 2024 Jan 22. . View in PubMed
  • Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children’s Oncology Group AREN18B5-Q Nat Commun. 2023 Dec 18; 14(1):8006. . View in PubMed
  • Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5 Cancer. 2023 Nov 07. . View in PubMed
  • Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532 Cancer. 2023 Oct 30. . View in PubMed
  • The Genetic and Epigenetic Features of Bilateral Wilms Tumor Predisposition: A Report from the Children’s Oncology Group AREN18B5-Q Study Res Sq. 2023 Mar 16. . View in PubMed
  • Children’s Oncology Group’s 2023 blueprint for research: Renal tumors Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30586. . View in PubMed
  • Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy J Clin Oncol. 2023 09 10; 41(26):4247-4256. . View in PubMed
  • BRAF Exon 15 Mutations in the Evaluation of Well-Differentiated Epithelial Nephroblastic Neoplasms in Children: A Report From the Children’s Oncology Group Study AREN03B2 Arch Pathol Lab Med. 2023 12 20. . View in PubMed
  • Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects Biometrics. 2022 12; 78(4):1441-1453. . View in PubMed
  • Authors’ Reply to the Letter to the Editor by Daniel MGreen. J Natl Compr Canc Netw. 2022 03; 20(3):xlvii-xlviii. . View in PubMed
  • Genetic changes associated with relapse in favorable histology Wilms tumor: A Children’s Oncology Group AREN03B2 study Cell Rep Med. 2022 06 21; 3(6):100644. . View in PubMed
  • Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children’s Oncology Group Trial, AREN0533 J Clin Oncol. 2022 09 10; 40(26):3047-3056. . View in PubMed
  • Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor J Natl Compr Canc Netw. 2021 08 01; 19(8):978-985. . View in PubMed
  • Point and interval estimation in two-stage adaptive designs with time to event data and biomarker-driven subpopulation selection Stat Med. 2020 08 30; 39(19):2568-2586. . View in PubMed
  • Reply to DM. Green. J Clin Oncol. 2020 03 01; 38(7):773-774. . View in PubMed
  • Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer Cancer Causes Control. 2019 Jul; 30(7):757-765. . View in PubMed
  • Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children’s Oncology Group JCO Precis Oncol. 2019; 3. . View in PubMed
  • On the need to adjust for multiplicity in confirmatory clinical trials with master protocols Ann Oncol. 2019 04 01; 30(4):506-509. . View in PubMed
  • Duration of Adjuvant Chemotherapy for Stage III Colon Cancer N Engl J Med. 2018 Mar 29; 378(13):1177-1188. . View in PubMed
  • Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database Eur J Cancer. 2018 11; 103:205-213. . View in PubMed
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project J Natl Cancer Inst. 2018 06 01; 110(6):638-648. . View in PubMed
  • A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer Clin Cancer Res. 2018 01 15; 24(2):316-325. . View in PubMed
  • Definitions and statistical properties of master protocols for personalized medicine in oncology J Biopharm Stat. 2018; 28(2):217-228. . View in PubMed
  • Point estimation following two-stage adaptive threshold enrichment clinical trials Stat Med. 2018 09 30; 37(22):3179-3196. . View in PubMed
  • Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer J Clin Oncol. 2017 Aug 10; 35(23):2624-2630. . View in PubMed
  • Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database J Clin Oncol. 2017 Jun 10; 35(17):1929-1937. . View in PubMed
  • Anorectal Function and Quality of Life in Patients With Early Stage Rectal Cancer Treated With Chemoradiation and Local Excision Dis Colon Rectum. 2017 May; 60(5):459-468. . View in PubMed
  • Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer Clin Colorectal Cancer. 2017 03; 16(1):23-30. . View in PubMed
  • Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples Ann Oncol. 2017 01 01; 28(1):34-43. . View in PubMed
  • Precision oncology: A new era of cancer clinical trials Cancer Lett. 2017 02 28; 387:121-126. . View in PubMed
  • Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials Chin Clin Oncol. 2016 Dec; 5(6):80. . View in PubMed
  • Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database J Clin Oncol. 2016 Apr 10; 34(11):1182-9. . View in PubMed
  • Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database J Clin Oncol. 2016 Mar 10; 34(8):843-53. . View in PubMed
  • Clinical trial designs incorporating predictive biomarkers Cancer Treat Rev. 2016 Feb; 43:74-82. . View in PubMed
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database J Clin Oncol. 2016 Jan 10; 34(2):144-50. . View in PubMed
  • Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database J Geriatr Oncol. 2016 11; 7(6):422-429. . View in PubMed
  • Surrogate End Points in Soft Tissue Sarcoma: Methodologic Challenges J Clin Oncol. 2016 11 10; 34(32):3949-3950. . View in PubMed
  • Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial Lancet Oncol. 2015 Nov; 16(15):1537-1546. . View in PubMed
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer J Thorac Oncol. 2015 Jul; 10(7):1099-106. . View in PubMed
  • Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population† Ann Oncol. 2015 May; 26(5):950-958. . View in PubMed
  • Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points J Biopharm Stat. 2015; 25(4):857-77. . View in PubMed
  • ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer J Natl Cancer Inst. 2014 Dec; 106(12). . View in PubMed
  • Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) CollaborationProjecting analysis dates for the IDEA collaboration. Forum Clin Oncol. 2014 Dec; 5(2):1-7. . View in PubMed
  • Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer Pharmacoeconomics. 2014 Dec; 32(12):1231-43. . View in PubMed
  • Center-Within-Trial Versus Trial-Level Evaluation of Surrogate Endpoints Comput Stat Data Anal. 2014 Oct 01; 78:1-20. . View in PubMed
  • Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program J Clin Oncol. 2014 Sep 20; 32(27):2975-84. . View in PubMed
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer Gastroenterology. 2014 Sep; 147(3):637-45. . View in PubMed
  • Genetic markers of treatment response to tumour necrosis factor-a inhibitors in the treatment of psoriasis Clin Exp Dermatol. 2014 Jun; 39(4):519-24. . View in PubMed
  • Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients Oncologist. 2014 May; 19(5):492-7. . View in PubMed
  • Adaptive randomized phase II design for biomarker threshold selection and independent evaluation Chin Clin Oncol. 2014 Mar; 3(1):3. . View in PubMed
  • Adaptive randomized phase II design for biomarker threshold selection and independent evaluation Chin Clin Oncol. 2014 Mar 01; 3(1). . View in PubMed
  • MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial PLoS One. 2014; 9(10):e108483. . View in PubMed
  • Germline variation in colorectal risk Loci does not influence treatment effect or survival in metastatic colorectal cancer PLoS One. 2014; 9(4):e94727. . View in PubMed
  • Mining the ACCENT database: a review and update Chin Clin Oncol. 2013 Jun; 2(2):18. . View in PubMed
  • Chronic consequences of acute injuries: worse survival after discharge J Trauma Acute Care Surg. 2012 Sep; 73(3):699-703. . View in PubMed
  • Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials Stat Med. 2012 Apr 13; 31(8):743-61. . View in PubMed
  • Bayesian adaptive trial design for a newly validated surrogate endpoint Biometrics. 2012 Mar; 68(1):258-67. . View in PubMed
  • Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis Br J Dermatol. 2010 Nov; 163(5):1056-63. . View in PubMed
  • Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser Arch Dermatol. 1993 Feb; 129(2):182-8. . View in PubMed
  • Ulcerative lichen planus-like dermatitis associated with hydroxyurea J Am Acad Dermatol. 1991 Jan; 24(1):143-5. . View in PubMed